Radiation Oncology, University Hospitals Leuven/KU Leuven, Leuven, Belgium.
Radiation Related Research, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
Lancet Oncol. 2014 Dec;15(13):e620-e624. doi: 10.1016/S1470-2045(14)70345-6. Epub 2014 Nov 24.
As the prognosis of lung cancer patients improves, more patients are at risk of developing local recurrence or a new primary tumour in previously irradiated areas. Technological advances in radiotherapy and imaging have made treatment of patients with high-dose re-irradiation possible, with the aim of long-term disease-free survival and even cure. However, high-dose re-irradiation with overlapping volumes of previously irradiated tissues is not without risks. Late, irreversible, and potentially serious normal tissue damage may occur because of injury to surrounding thoracic structures and organs at risk. In this Review, we aimed to report the efficacy and toxic effects of high-dose re-irradiation for locoregional recurrent non-small-cell lung cancer. Our findings indicate that high-dose re-irradiation might be beneficial in selected patients; however, patients and physicians should be aware of the scarcity of high-quality data when considering this treatment.
随着肺癌患者预后的改善,越来越多的患者有在先前照射区域发生局部复发或新原发性肿瘤的风险。放射治疗和影像学技术的进步使得对高剂量再照射患者进行治疗成为可能,其目的是实现长期无疾病生存甚至治愈。然而,对先前照射组织的重叠区域进行高剂量再照射并非没有风险。由于对周围胸部结构和危及器官的损伤,可能会发生迟发性、不可逆转且潜在严重的正常组织损伤。在这篇综述中,我们旨在报告高剂量再照射治疗局部复发性非小细胞肺癌的疗效和毒副作用。我们的研究结果表明,高剂量再照射可能对某些患者有益;然而,在考虑这种治疗方法时,患者和医生应该意识到高质量数据的缺乏。